Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Ureteral Neoplasms × Observation × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 13 Prostatic Neoplasms 8 Endometrial Neoplasms 8 Breast Neoplasms 7 Leukemia, Myeloid, Acute 6 Oropharyngeal Neoplasms 5 Lung Neoplasms 5 Neoplasms 4 Neoplasm Metastasis 4 Multiple Myeloma 4 Melanoma 4 Lymphoma, Large B-Cell, Diffuse 4 Colonic Neoplasms 4 Stomach Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Neuroblastoma 3 Mouth Neoplasms 3 Lymphoma, Mantle-Cell 3 Esophageal Neoplasms 3 Colorectal Neoplasms 3 Brain Neoplasms 3 Anus Neoplasms 3 Uterine Cervical Neoplasms 2 Urinary Bladder Neoplasms 2 Squamous Intraepithelial Lesions 2 Sarcoma 2 Recurrence 2 Pathologic Complete Response 2 Pancreatic Neoplasms 2 Motor Activity 2

Interventions

Specimen Handling 9 Gemcitabine 9 pembrolizumab 7 enfortumab vedotin 7 Magnetic Resonance Spectroscopy 7 Cisplatin 6 Carboplatin 5 vinflunine 4 avelumab 4 Immunoglobulin G 3 Disulfides 3 Biopsy 3 eribulin 2 cabozantinib 2 atezolizumab 2 Standard of Care 2 Ramucirumab 2 Platinum 2 Nivolumab 2 Nephroureterectomy 2 Ipilimumab 2 Docetaxel 2 CTLA-4 Antigen 2 Bortezomib 2 1,2-diaminocyclohexaneplatinum II citrate 2 vandetanib 1 tremelimumab 1 tocilizumab 1 tamibarotene 1 rucaparib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03244384 2026-03-18

AMBASSADOR

National Cancer Institute (NCI)

Phase 3 Active not recruiting

Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡